Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-RIZATRIPTAN RPD | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2020-07-06 | 490 |
APO-RIZATRIPTAN RPD | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2018-09-11 | 493 |
APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-03-12 | 2017-03-31 | 725 |
APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-04-24 | 2017-06-13 | 7716 |
APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-05-02 | 2017-08-16 | 8710 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-05-02 | 2017-08-17 | 8713 |
APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2023-08-12 | 2023-08-23 | 201710 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-08-23 | 2023-09-01 | 202827 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-06-13 | 2024-07-05 | 230492 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-11-15 | 2025-02-14 | 243190 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-12-18 | 2020-03-09 | 101517 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2022-12-16 | 2023-01-06 | 178763 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-03-23 | 2023-04-27 | 187730 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-04-27 | 2023-05-06 | 190865 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-05-19 | 2023-06-16 | 192812 |
APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2019-02-13 | 2019-03-07 | 75629 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-04-18 | 2019-05-13 | 82019 |
APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-11-07 | 2018-03-20 | 28440 |
APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-11-28 | 2018-02-27 | 30960 |
APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-11-28 | 2018-03-13 | 31031 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |